Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor.

Podolin PL, Bolognese BJ, Foley JF, Long E 3rd, Peck B, Umbrecht S, Zhang X, Zhu P, Schwartz B, Xie W, Quinn C, Qi H, Sweitzer S, Chen S, Galop M, Ding Y, Belyanskaya SL, Israel DI, Morgan BA, Behm DJ, Marino JP Jr, Kurali E, Barnette MS, Mayer RJ, Booth-Genthe CL, Callahan JF.

Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:25-31. doi: 10.1016/j.prostaglandins.2013.02.001. Epub 2013 Feb 19.

PMID:
23434473
2.

A noninvasive [99mTc]DTPA SPECT/CT imaging methodology as a measure of lung permeability in a guinea pig model of COPD.

Wu Y, Kotzer CJ, Makrogiannis S, Logan GA, Haley H, Barnette MS, Sarkar SK.

Mol Imaging Biol. 2011 Oct;13(5):923-9. doi: 10.1007/s11307-010-0423-9.

PMID:
20838905
3.

The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.

Davis TG, Peterson JJ, Kou JP, Capper-Spudich EA, Ball D, Nials AT, Wiseman J, Solanke YE, Lucas FS, Williamson RA, Ferrari L, Wren P, Knowles RG, Barnette MS, Podolin PL.

J Pharmacol Exp Ther. 2009 Sep;330(3):922-31. doi: 10.1124/jpet.109.152454. Epub 2009 Jun 4.

PMID:
19498103
4.

Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage.

Tudhope SJ, Finney-Hayward TK, Nicholson AG, Mayer RJ, Barnette MS, Barnes PJ, Donnelly LE.

J Pharmacol Exp Ther. 2008 Jan;324(1):306-12. Epub 2007 Oct 5.

PMID:
17921189
5.

Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD8+ T-lymphocytes.

Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA.

Mol Pharmacol. 2004 Dec;66(6):1679-89. Epub 2004 Sep 15.

PMID:
15371556
6.

Cytokines modulate cilomilast response in lung fibroblasts.

Kohyama T, Liu X, Wen FQ, Kobayashi T, Fang Q, Abe S, Cieslinski L, Barnette MS, Rennard SI.

Clin Immunol. 2004 Jun;111(3):297-302.

PMID:
15183150
7.

Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.

Oger S, Méhats C, Barnette MS, Ferré F, Cabrol D, Leroy MJ.

Biol Reprod. 2004 Feb;70(2):458-64. Epub 2003 Oct 15.

PMID:
14561639
8.

Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells.

Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA.

Am J Physiol Lung Cell Mol Physiol. 2003 Feb;284(2):L279-89. Epub 2002 Oct 4.

9.

PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels.

Kohyama T, Liu X, Wen FQ, Zhu YK, Wang H, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS, Rennard SI.

Am J Respir Cell Mol Biol. 2002 Jun;26(6):694-701.

PMID:
12034568
10.

New phosphodiesterase inhibitors as therapeutics for the treatment of chronic lung disease.

Barnette MS, Underwood DC.

Curr Opin Pulm Med. 2000 Mar;6(2):164-9. Review.

PMID:
10741778
11.
12.

Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.

Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, Torphy TJ, Barnette MS.

Br J Pharmacol. 1999 Dec;128(7):1393-8.

13.

Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic.

Torphy TJ, Barnette MS, Underwood DC, Griswold DE, Christensen SB, Murdoch RD, Nieman RB, Compton CH.

Pulm Pharmacol Ther. 1999;12(2):131-5. Review. No abstract available.

PMID:
10373396
14.

Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques.

Reape TJ, Rayner K, Manning CD, Gee AN, Barnette MS, Burnand KG, Groot PH.

Am J Pathol. 1999 Feb;154(2):365-74.

15.

1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosophodiesterase 4 for the treatment of asthma.

Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinski JM, DeWolf WE Jr, Barnette MS, Underwood DC, Griswold DE, Cieslinski LB, Burman M, Bochnowicz S, Osborn RR, Manning CD, Grous M, Hillegas LM, Bartus JO, Ryan MD, Eggleston DS, Haltiwanger RC, Torphy TJ.

J Med Chem. 1998 Mar 12;41(6):821-35.

PMID:
9526558
16.

SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions.

Barnette MS, Christensen SB, Essayan DM, Grous M, Prabhakar U, Rush JA, Kagey-Sobotka A, Torphy TJ.

J Pharmacol Exp Ther. 1998 Jan;284(1):420-6.

PMID:
9435206
17.

Characterization of functional chemokine receptors (CCR1 and CCR2) on EoL-3 cells: a model system to examine the role of chemokines in cell function.

Sarau HM, Rush JA, Foley JJ, Brawner ME, Schmidt DB, White JR, Barnette MS.

J Pharmacol Exp Ther. 1997 Oct;283(1):411-8.

PMID:
9336350
18.

Association of the anti-inflammatory activity of phosphodiesterase 4 (PDE4) inhibitors with either inhibition of PDE4 catalytic activity or competition for [3H]rolipram binding.

Barnette MS, Bartus JO, Burman M, Christensen SB, Cieslinski LB, Esser KM, Prabhakar US, Rush JA, Torphy TJ.

Biochem Pharmacol. 1996 Apr 12;51(7):949-56.

PMID:
8651945
19.

Prolonged beta adrenoceptor stimulation up-regulates cAMP phosphodiesterase activity in human monocytes by increasing mRNA and protein for phosphodiesterases 4A and 4B.

Manning CD, McLaughlin MM, Livi GP, Cieslinski LB, Torphy TJ, Barnette MS.

J Pharmacol Exp Ther. 1996 Feb;276(2):810-8.

PMID:
8632354
20.
21.
22.

The ability of phosphodiesterase IV inhibitors to suppress superoxide production in guinea pig eosinophils is correlated with inhibition of phosphodiesterase IV catalytic activity.

Barnette MS, Manning CD, Cieslinski LB, Burman M, Christensen SB, Torphy TJ.

J Pharmacol Exp Ther. 1995 May;273(2):674-9.

PMID:
7752069
23.

Lipid mediators: mechanisms.

Glaser KB, Barnette MS.

Agents Actions Suppl. 1995;47:185-8. No abstract available.

PMID:
7785497
24.

Phosphodiesterase IV inhibitors as therapy for eosinophil-induced lung injury in asthma.

Torphy TJ, Barnette MS, Hay DW, Underwood DC.

Environ Health Perspect. 1994 Dec;102 Suppl 10:79-84.

25.

Effects of scalaradial, a novel inhibitor of 14 kDa phospholipase A2, on human neutrophil function.

Barnette MS, Rush J, Marshall LA, Foley JJ, Schmidt DB, Sarau HM.

Biochem Pharmacol. 1994 Apr 29;47(9):1661-7.

PMID:
8185681
26.

Initial biochemical and functional characterization of cyclic nucleotide phosphodiesterase isozymes in canine colonic smooth muscle.

Barnette MS, Manning CD, Price WJ, Barone FC.

J Pharmacol Exp Ther. 1993 Feb;264(2):801-12.

PMID:
7679736
27.
28.

5-Hydroxytryptamine (5-HT) and SK&F 103829 contract canine lower esophageal sphincter smooth muscle by stimulating 5-HT2 receptors.

Barnette MS, Grous M, Manning CD, Price WJ, Nelson AH, Bondinell WE, Barone FC, Ormsbee HS 3rd.

Receptor. 1992 Fall;2(3):155-67.

PMID:
1472950
29.

Human lower oesophageal sphincter relaxation is associated with raised cyclic nucleotide content.

Barnette MS, Barone FC, Fowler PJ, Grous M, Price WJ, Ormsbee HS.

Gut. 1991 Jan;32(1):4-9.

30.

Inhibition of neuronally induced relaxation of canine lower esophageal sphincter by opioid peptides.

Barnette MS, Grous M, Manning CD, Callahan JF, Barone FC.

Eur J Pharmacol. 1990 Jul 3;182(2):363-8.

PMID:
2204537
31.

Activation of cyclic AMP-dependent protein kinase during canine lower esophageal sphincter relaxation.

Barnette MS, Grous M, Torphy TJ, Ormsbee HS 3rd.

J Pharmacol Exp Ther. 1990 Mar;252(3):1160-6.

PMID:
2156993
32.

Cyclic nucleotide-dependent protein kinases in the lower esophageal sphincter.

Miller CA, Barnette MS, Ormsbee HS 3rd, Torphy TJ.

Am J Physiol. 1986 Dec;251(6 Pt 1):G794-803.

PMID:
3024502
33.

Lower esophageal sphincter relaxation is associated with increased cyclic nucleotide content.

Torphy TJ, Fine CF, Burman M, Barnette MS, Ormsbee HS 3rd.

Am J Physiol. 1986 Dec;251(6 Pt 1):G786-93.

PMID:
3024501
34.
35.

Inhibition of calmodulin activity by insect venom peptides.

Barnette MS, Daly R, Weiss B.

Biochem Pharmacol. 1983 Oct 1;32(19):2929-33.

PMID:
6313011
36.

Interaction of neuropeptides with calmodulin: a structure-activity study.

Barnette MS, Weiss B.

Psychopharmacol Bull. 1983;19(3):387-92. No abstract available.

PMID:
6138796
37.

Pharmacological regulation of calmodulin.

Weiss B, Prozialeck W, Cimino M, Barnette MS, Wallace TL.

Ann N Y Acad Sci. 1980;356:319-45. Review.

PMID:
6112947

Supplemental Content

Loading ...
Support Center